Antimicrobial Susceptibility of Clinical Isolates of Bacteroides fragilis Group Organisms Recovered from 2009 to 2012 in a Korean Hospital
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: Periodic monitoring of antimicrobial resistance trends of clinically important anaerobic bacteria such as Bacteroides fragilis group organisms is required. We determined the antimicrobial susceptibilities of clinical isolates of B. fragilis group organisms recovered from 2009 to 2012 in a tertiary-care hospital in Korea. Methods: A total of 180 nonduplicate clinical isolates of B. fragilis group organisms were collected in a tertiary care hospital. The species were identified by conventional methods: the ATB 32A rapid identification system (bioMérieux, France) and the Vitek MS matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (bioMérieux). Antimicrobial susceptibility was determined by the CLSI agar dilution method. Results: Imipenem and meropenem resistance rates were 0-6% for B. fragilis group isolates. The rate of resistance to piperacillin-tazobactam was 2% for B. fragilis and 0% for other Bacteroides species, but 17% for B. thetaiotaomicron isolates. High resistance rates to piperacillin (72% and 69%), cefotetan (89% and 58%), and clindamycin (83% and 69%) were observed for B. thetaiotaomicron and other Bacteroides spp. The moxifloxacin resistance rate was 27% for other Bacteroides spp. The MIC50 and MIC90 of tigecycline were 2-4 μg/mL and 8-16 μg/mL, respectively. No isolates were resistant to chloramphenicol or metronidazole. Conclusions: Imipenem, meropenem, chloramphenicol, and metronidazole remain active against B. fragilis group isolates. Moxifloxacin and tigecycline resistance rates are 2-27% and 8-15% for B. fragilis group isolates, respectively.
Abstract
Background: Periodic monitoring of antimicrobial resistance trends of clinically important anaerobic bacteria such as Bacteroides fragilis group organisms is required. We determined the antimicrobial susceptibilities of clinical isolates of B. fragilis group organisms recovered from 2009 to 2012 in a tertiary-care hospital in Korea. Methods: A total of 180 nonduplicate clinical isolates of B. fragilis group organisms were collected in a tertiary care hospital. The species were identified by conventional methods: the ATB 32A rapid identification system (bioMérieux, France) and the Vitek MS matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (bioMérieux). Antimicrobial susceptibility was determined by the CLSI agar dilution method. Results: Imipenem and meropenem resistance rates were 0-6% for B. fragilis group isolates. The rate of resistance to piperacillin-tazobactam was 2% for B. fragilis and 0% for other Bacteroides species, but 17% for B. thetaiotaomicron isolates. High resistance rates to piperacillin (72% and 69%), cefotetan (89% and 58%), and clindamycin (83% and 69%) were observed for B. thetaiotaomicron and other Bacteroides spp. The moxifloxacin resistance rate was 27% for other Bacteroides spp. The MIC50 and MIC90 of tigecycline were 2-4 μg/mL and 8-16 μg/mL, respectively. No isolates were resistant to chloramphenicol or metronidazole. Conclusions: Imipenem, meropenem, chloramphenicol, and metronidazole remain active against B. fragilis group isolates. Moxifloxacin and tigecycline resistance rates are 2-27% and 8-15% for B. fragilis group isolates, respectively.
참고문헌 (20)
- Treviño M, "Susceptibility trends of Bacteroides fragilis group and characterisation of carbapenemase-producing strains by automated REP-PCR and MALDI TOF", Anaerobe, 18, pp.37~43 (2012)
- Karlowsky JA, "Prevalence of antimicrobial resistance among clinical isolates of Bacteroides fragilis group in Canada in 2010-2011: CANWARD surveillance study", Antimicrob Agents Chemother, 56, pp.1247~1252 (2012)
- Nagy E, "Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 20 years of experience", Clin Microbiol Infect, 17, pp.371~379 (2011)
- Fille M, "Bacteroides fragilis group: trends in resistance", Curr Microbiol, 52, pp.153~157 (2006)
- Snydman DR, "National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004", Antimicrob Agents Chemother, 51, pp.1649~1655 (2007)
- 노경호, "Resistance Trends of Bacteroides fragilis Group Over an 8-Year Period, 1997-2004, in Korea", Annals of Laboratory Medicine, 29(4), pp.293~298 (2009), 대한진단검사의학회
- Fernández-Canigia L, "First national survey of antibiotic susceptibility of the Bacteroides fragilis group: emerging resistance to carbapenems in Argentina", Antimicrob Agents Chemother, 56, pp.1309~1314 (2012)
- Lee Y, "Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea", Antimicrob Agents Chemother, 54, pp.3993~3997 (2010)
- CLSI, "Methods for Antimicrobial susceptibility testing of anaerobic bacteria; Approved standard, 8th ed. CLSI document M11-A8", Clinical and Laboratory Standards Institute, ~ (2012)
- Seifert H, "German multicentre survey of the antibiotic susceptibility of Bacteroides fragilis group and Prevotella species isolated from intra-abdominal infections: results from the PRISMA study", J Antimicrob Chemother, 65, pp.2405~2410 (2010)
- Brook I, "Antianaerobic antimicrobials: spectrum and susceptibility testing", Clin Microbiol Rev, 26, pp.526~546 (2013)
- "FDA Approved Drug Products Label for TYGACIL, NDA no. 021821" (2013)[URL]
- "Breakpoint tables for interpretation of MICs and zone diameters. Version 3.1" (2013)[URL]
- Snydman DR, "Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007)", Clin Infect Dis, 50(Sl), pp.S26~33 (2010)
- Goldstein EJC, "Resistance trends in antimicrobial susceptibility of anaerobic bacteria, part II", Clinical Microbiology Newsletter, 33, pp.9~15 (2011)
- Betriu C, "Changing patterns of fluoroquinolone resistance among Bacteroides fragilis group organisms over a 6-year period (1997-2002)", Diagn Microbiol Infect Dis, 53, pp.221~223 (2005)
- 조선미, "Ceftriaxone-sulbactam의 주요 호기성 및 혐기성 임상 분리균주에 대한 시험관내 항균력", Laboratory Medicine Online, 1(4), pp.209~220 (2011), 대한진단검사의학회
- Wybo I, "Fourth Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria", J Antimicrob Chemother, 69, pp.155~161 (2014)
- Brazier JS, "Metronidazole resistance among clinical isolates belonging to the Bacteroides fragilis group: time to be concerned?", J Antimicrob Chemothery, 44, pp.580~581 (1999)
- Lee K, "Antimicrobial resistance patterns of Bacteroides fragilis group organisms in Korea", Yonsei Med J, 39, pp.578~586 (1998)